Anti-tumoral efficacy was higher for [225Ac]-PSMA TAT than for [177Lu]-PSMA TRNT, but toxicity to the salivary glands was also increased, leading to severe xerostomia (dry mouth syndrome) as the dose-limiting toxicity. Here, FOLH1 is linked to xerostomia.